Kenny Mikael Hansson

Title: Kenny Mikael Hansson: Innovator in RNA Therapeutics

Introduction

Kenny Mikael Hansson is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of RNA therapeutics, particularly in the development of modified RNA molecules. With a total of 2 patents, his work focuses on innovative solutions for medical treatments.

Latest Patents

Hansson's latest patents include "Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto." This patent discloses modified RNA molecules that encode VEGF-A polypeptides and formulations that include these modified RNA molecules. The applications of this invention are particularly relevant for treating diseases that respond to VEGF-A therapy. Another significant patent is "Lipid nanoparticles for delivering modified RNA encoding a VEGF-A polypeptide." This patent describes nanoparticles that consist of a lipid component and modified RNA, aimed at improving wound healing in subjects.

Career Highlights

Kenny Mikael Hansson is currently associated with Modernatx, Inc., where he continues to advance his research in RNA technologies. His work is pivotal in the ongoing development of therapeutic applications that leverage modified RNA for medical benefits.

Collaborations

Hansson collaborates with esteemed colleagues such as Leif Karlsson Parinder and Regina Desirée Fritsche Danielson, contributing to a dynamic research environment that fosters innovation.

Conclusion

Kenny Mikael Hansson's contributions to RNA therapeutics exemplify the impact of innovative thinking in medicine. His patents reflect a commitment to advancing healthcare solutions through scientific research and collaboration.